skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor

Authors:
; ; ; ; ; ; ; ; ; ; ; ;
Publication Date:
Research Org.:
Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Org.:
NSFNIH
OSTI Identifier:
1419870
Resource Type:
Journal Article
Resource Relation:
Journal Name: Nature Communications; Journal Volume: 9; Journal Issue: 1
Country of Publication:
United States
Language:
ENGLISH

Citation Formats

Khandelwal, Anuj, Kent, Caitlin N., Balch, Maurie, Peng, Shuxia, Mishra, Sanket J., Deng, Junpeng, Day, Victor W., Liu, Weiya, Subramanian, Chitra, Cohen, Mark, Holzbeierlein, Jeffery M., Matts, Robert, and Blagg, Brian S. J.. Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor. United States: N. p., 2018. Web. doi:10.1038/s41467-017-02013-1.
Khandelwal, Anuj, Kent, Caitlin N., Balch, Maurie, Peng, Shuxia, Mishra, Sanket J., Deng, Junpeng, Day, Victor W., Liu, Weiya, Subramanian, Chitra, Cohen, Mark, Holzbeierlein, Jeffery M., Matts, Robert, & Blagg, Brian S. J.. Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor. United States. doi:10.1038/s41467-017-02013-1.
Khandelwal, Anuj, Kent, Caitlin N., Balch, Maurie, Peng, Shuxia, Mishra, Sanket J., Deng, Junpeng, Day, Victor W., Liu, Weiya, Subramanian, Chitra, Cohen, Mark, Holzbeierlein, Jeffery M., Matts, Robert, and Blagg, Brian S. J.. 2018. "Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor". United States. doi:10.1038/s41467-017-02013-1.
@article{osti_1419870,
title = {Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor},
author = {Khandelwal, Anuj and Kent, Caitlin N. and Balch, Maurie and Peng, Shuxia and Mishra, Sanket J. and Deng, Junpeng and Day, Victor W. and Liu, Weiya and Subramanian, Chitra and Cohen, Mark and Holzbeierlein, Jeffery M. and Matts, Robert and Blagg, Brian S. J.},
abstractNote = {},
doi = {10.1038/s41467-017-02013-1},
journal = {Nature Communications},
number = 1,
volume = 9,
place = {United States},
year = 2018,
month = 1
}
  • The inhibition of PKC-{zeta} has been proposed to be a potential drug target for immune and inflammatory diseases. A series of 2-(6-phenyl-1H indazol-3-yl)-1H-benzo[d]imidazoles with initial high crossover to CDK-2 has been optimized to afford potent and selective inhibitors of protein kinase c-zeta (PKC-{zeta}). The determination of the crystal structures of key inhibitor:CDK-2 complexes informed the design and analysis of the series. The most selective and potent analog was identified by variation of the aryl substituent at the 6-position of the indazole template to give a 4-NH{sub 2} derivative. The analog displays good selectivity over other PKC isoforms ({alpha}, {beta}II, {gamma},more » {delta}, {epsilon}, {mu}, {theta}, {eta} and {ell}/{lambda}) and CDK-2, however it displays marginal selectivity against a panel of other kinases (37 profiled).« less
  • Discriminating closely related molecules remains a major challenge in the engineering of binding proteins and inhibitors. Here we report the development of highly selective inhibitors of small ubiquitin-related modifier (SUMO) family proteins. SUMOylation is involved in the regulation of diverse cellular processes. Functional differences between two major SUMO isoforms in humans, SUMO1 and SUMO2/3, are thought to arise from distinct interactions mediated by each isoform with other proteins containing SUMO-interacting motifs (SIMs). However, the roles of such isoform-specific interactions are largely uncharacterized due in part to the difficulty in generating high-affinity, isoform-specific inhibitors of SUMO/SIM interactions. We first determined themore » crystal structure of a 'monobody,' a designed binding protein based on the fibronectin type III scaffold, bound to the yeast homolog of SUMO. This structure illustrated a mechanism by which monobodies bind to the highly conserved SIM-binding site while discriminating individual SUMO isoforms. Based on this structure, we designed a SUMO-targeted library from which we obtained monobodies that bound to the SIM-binding site of human SUMO1 with K{sub d} values of approximately 100 nM but bound to SUMO2 400 times more weakly. The monobodies inhibited SUMO1/SIM interactions and, unexpectedly, also inhibited SUMO1 conjugation. These high-affinity and isoform-specific inhibitors will enhance mechanistic and cellular investigations of SUMO biology.« less
  • The integral membrane enzyme fatty acid amide hydrolase (FAAH) hydrolyzes the endocannabinoid anandamide and related amidated signaling lipids. Genetic or pharmacological inactivation of FAAH produces analgesic, anxiolytic, and antiinflammatory phenotypes but not the undesirable side effects of direct cannabinoid receptor agonists, indicating that FAAH may be a promising therapeutic target. Structure-based inhibitor design has, however, been hampered by difficulties in expressing the human FAAH enzyme. Here, we address this problem by interconverting the active sites of rat and human FAAH using site-directed mutagenesis. The resulting humanized rat (h/r) FAAH protein exhibits the inhibitor sensitivity profiles of human FAAH but maintainsmore » the high-expression yield of the rat enzyme. We report a 2.75-{angstrom} crystal structure of h/rFAAH complexed with an inhibitor, N-phenyl-4-(quinolin-3-ylmethyl)piperidine-1-carboxamide (PF-750), that shows strong preference for human FAAH. This structure offers compelling insights to explain the species selectivity of FAAH inhibitors, which should guide future drug design programs.« less